Results 101 to 110 of about 54,207 (313)

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang, Umar Raza, Jia Song, Junyan Lu, Shun Yao, Xiaohong Liu, Wei Zhang, Shujuan Li   +7 more
wiley   +1 more source

Dasatinib‐induced chylothorax in a patient with chronic myeloid leukaemia: a case report and literature review

Respirology Case Reports, 2021
Dasatinib is a potent and effective second‐generation oral tyrosine kinase inhibitor that is clinically indicated for the treatment of imatinib‐resistant or imatinib‐intolerant breakpoint cluster region‐Abelson (BCR‐ABL)‐positive chronic myeloid ...
Chao‐Chin Hsu, Jui‐Feng Hsu, Kuan‐Li Wu   +2 more
doaj   +1 more source

Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622.

Journal of Clinical Oncology, 2018
Purpose Addition of imatinib to intensive chemotherapy improved survival for children and young adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
W. Slayton, K. Schultz, J. Kairalla, M. Devidas, X. Mi, M. Pulsipher, B. Chang, C. Mullighan, I. Iacobucci, L. Silverman, M. Borowitz, A. Carroll, N. Heerema, J. Gastier-Foster, B. Wood, Sherri L. Mizrahy, T. Merchant, V. Brown, L. Sieger, M. Siegel, E. Raetz, N. Winick, M. Loh, W. Carroll, S. Hunger   +24 more
semanticscholar   +1 more source

A Phase I Trial of Dasatinib and Osimertinib in TKI Naïve Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer

Frontiers in Oncology, 2021
Background Osimertinib is an effective first-line therapy option for EGFR-mutant NSCLC, but virtually all patients develop resistance. CRIPTO, through Src activation, has been implicated in resistance to EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy.
C. Kim, Stephen V. Liu, J. Crawford, T. Torres, Vincent Chen, J. Thompson, M. Tan, G. Esposito, Deepa S. Subramaniam, G. Giaccone   +9 more
semanticscholar   +1 more source

Predictive biomarkers for dasatinib treatment in melanoma [PDF]

Oncoscience, 2014
Dasatinib has anti-proliferative and anti-invasive effects in melanoma cell lines. However clinical trials have shown modest activity for dasatinib in metastatic melanoma. Although dasatinib targets SRC kinase, neither expression nor phosphorylation of SRC appears to predict response to dasatinib.
Thamir Mahgoub, John Crown, Norma O'Donovan, Lorraine O'Driscoll, Alex J Eustace, Susan Kennedy, D. Tryfonopoulos, Martin Clynes, Annemarie Larkin   +8 more
openaire   +5 more sources

Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targets. [PDF]

, 2017
BackgroundLiposarcoma, the most common soft tissue tumor, is understudied cancer, and limited progress has been made in the treatment of metastatic disease.
Doan, Ngan B, Forscher, Charles, Garg, Manoj, Kanojia, Deepika, Koeffler, H Phillip, Luty, Samuel B, M T, Anand, Martinez, Jacqueline, Said, Jonathan W, Tyner, Jeffrey W   +9 more
core   +2 more sources

Cardiovascular toxicity induced by TKIs in patients with chronic myeloid leukaemia: Are women and men different?

ESC Heart Failure, Volume 12, Issue 2, Page 1447-1454, April 2025.
This study analyzes 148 patients (66 women and 82 men) with chronic myeloid leukemia treated with tyrosine kinase inhibitors, focusing on cardiovascular adverse events. The risk assessment, performed using the HFA/ICOS score, reveals sex‐specific differences: venous thrombosis is more common in women, while arterial thrombosis predominates in men.
Cristina Madaudo, Daniela Di Lisi, Antonio Cannatà, Federica Manfrè, Celeste Vullo, Marco Santoro, Ciro Botta, Salvatrice Mancuso, Sergio Siragusa, Alfredo Ruggero Galassi, Giuseppina Novo   +10 more
wiley   +1 more source

Therapeutic targeting of chromatin alterations in leukemia and solid tumors

International Journal of Cancer, EarlyView.
Abstract Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...
Florian Perner, Tobias Berg, Daniel Sasca, Sophie‐Luise Mersiowsky, Jayant Y. Gadrey, Johanna Thomas, Michael W. M. Kühn, Michael Lübbert   +7 more
wiley   +1 more source

Dasatinib Approved for Pediatric CML [PDF]

Cancer Discovery, 2018
Abstract The FDA approved dasatinib to treat pediatric chronic myeloid leukemia. This drug is the second tyrosine kinase inhibitor, alongside imatinib, approved for this indication and represents an important new option for first- and second-line treatment.
openaire   +2 more sources

Body mass index does not impact on molecular response rate of chronic myeloid leukaemia patients treated frontline with second generation tyrosine kinase inhibitors. [PDF]

, 2017
..
Alimena G, Breccia M., Canichella M, Colafigli G, Diverio D, Foà R, Latagliata R, Molica M   +7 more
core   +1 more source